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Background: Since the introduction of sentinel lymph node biopsy (SLNB), its use as a standard of care for patients
with clinically node-negative cutaneous melanoma remains controversial. We wished to evaluate our experience of
SLNB for melanoma.
Methods: A single center observational cohort of 203 melanoma patients with a primary cutaneous melanoma
(tumour thickness > 1 mm) and without clinical evidence of metastasis was investigated from 2002 to 2009. Head
and neck melanoma were excluded. SLN was identified following preoperative lymphoscintigraphy and
intraoperative gamma probe interrogation.
Results: The SLN identification rate was 97%. The SLN was tumor positive in 44 patients (22%). Positive SLN was
significantly associated with primary tumor thickness and microscopic ulceration. The median follow-up was 39.5
(5–97) months. Disease progression was significantly more frequent in SLN positive patients (32% vs 13%, p = 0.002).
Five-year DFS and OS of the entire cohort were 79.6% and 84.6%, respectively, with a statistical significant
difference between SLN positive (58.7% and 69.7%) and SLN negative (85% and 90.3%) patients (p = 0.0006 and
p = 0.0096 respectively). Postoperative complications after SLNB were observed in 12% of patients.
Conclusion: Our data confirm previous studies and support the clinical usefulness of SLNB as a reliable and
accurate staging method in patients with cutaneous melanoma. However, the benefit of additional CLND in
patients with positive SLN remains to be demonstrated.
Keywords: Melanoma, Sentinel lymph nodeBackground
Since its introduction in 1992 [1], the role of sentinel
lymph node biopsy (SLNB) in melanoma care remains
controversial and is not included in most guidelines for
the management of melanoma in Europe [2]. Its main
short term aim is the early identification of patients with
occult nodal metastasis, known as micrometastasis, who
might benefit from complete lymph node dissection
(CLND). The long term aim is to provide a more accur-
ate basis for formulating a prognosis than do standard* Correspondence: francois.aubin@univ-fcomte.fr
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distribution, and reproduction in any mediumdemographic and histopathological factors. Furthermore,
the presence or absence of micrometastases in the senti-
nel lymph node (SLN) is critical to both accurate AJCC
staging2 and decisions regarding adjuvant therapy and
follow-up regimens. The final version of melanoma sta-
ging and classification takes into account the results of
SLNB [3]. A Cox multivariate analysis of 3,307 stage III
patients demonstrated that 5-year survival rates ranged
from 70% for patients with micrometastasis (T1-
T4N1aM0) to 39% for patients with T1-T4N3M0 CM.
However, according to the Multicenter Selective Lym-
phadenectomy Trial (MSLT) [4], there was no significant
difference in disease-specific survival between patients
with lymphatic mapping by SLNB (and immediate
CLND) and patients with nodal observation. Othertral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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influence of SLNB and CLND on long term patient sur-
vival as well as its therapeutic role are still debated [5].
Despite the fact that SLNB is widely used in France
[2], there are no French studies reporting the experience
of SLNB. We present our 8-year consecutive clinical ex-
perience of performing SLNB for CM. We evaluated the
outcome of patients in terms of disease progression and
mortality based on the SLNB result.
Methods
Patients
SLNB has been performed at Besançon University Hos-
pital since 2000. Patients who had undergone this tech-
nique in the first two years were excluded to allow the
medical team to gain experience in guaranteeing repro-
ducibility and reliability of the results [4]. Only patients
with a primary cutaneous melanoma (tumour thickness
> 1 mm) and without clinical evidence of metastasis who
underwent SLNB between January 2002 and December
2009 were included. Furthermore, patients with head
and neck CM were also excluded because of the com-
plexity of lymphatic drainage, multi-site drainage and
the high number of false negatives [6,7]. Since this retro-
spective study was conducted in France, it was not eli-
gible for submission to our research ethics committee.
Patients were selected and each clinical file obtained
from the Cancer Registry of the Besançon University
Hospital (authorization from the Privacy and Data Pro-
tection National Agency, CNIL number 903417) was
re-examined and the following data were collected: epi-
demiological criteria (sex, age), histological criteria, clinical
features, SLN status (positive or negative), results of
CLND and evolution criteria (relapse and survival). The
epidemiological and histological data were collected from
the Cancer Registry, whereas the evolution criteria were
gathered from the hospital clinical files or by writing to
family practitioners.
SLNB procedure
After information and written consent, preoperative
lymphoscintigraphy was performed in all patients by
injecting 1 mL of technetium Tc 99 m-labeled sulfur col-
loid intradermally around the periphery of the primary
lesion or biopsy scar in 4-quadrant fashion. Using a
gamma camera with a low-energy, high resolution colli-
mator, dynamic and static images were obtained, begin-
ning 15 minutes after injection and continuing every
30 minutes thereafter, until the SLNs were visualized.
Surgery took place the following day. A hand-held
gamma probe was used to localize the SLN transcuta-
neously. The SLN was identified intra-operatively using
a gamma probe. After SLN harvesting, the radioactive
count was measured ex vivo using the gamma probe.Echelon nodes were then harvested if they had a
count ≥ 10% of the SLN. The background count of the
lymph node basin was then measured to ensure that no fur-
ther radioactive nodes remained. In addition to preopera-
tive lymphoscintigraphy, 9 patients received an on-table
injection of patent Blue V dye (Laboratoire Guerbet,
Aulnay-sous-Bois, France) around the biopsy scar. Follo-
wing completion of SLN dissection, the maximal counts
per second in vivo and ex vivo were recorded to verify that
no areas of increased radioactivity remained.
Histopathologic evaluation
Pathological analysis of SLN involved an initial bisection
of the node along its hilum after fixation. Then, from
each side of the SLN, five serial step sections of 4 mm
were cut with 50 mm intervals between different num-
bers of sections. Finally, all sections were stained with
hematoxylin and eosin. All slides were examined histolo-
gically, and if melanoma cells were detected immunohis-
tochemistry (S100, HMB45 and MelanA) was then
performed for confirmation.
Surgical and adjuvant therapy
Patients with positive SLNs were advised to have CLND
of the regional basin. According to French guidelines, all
patients with primary CM larger than or equal to
1.5 mm in thickness as well as patients with positive
SLN and positive CLND and patients with high-risk pri-
mary melanoma (tumor thickness > 4 mm and ulcer-
ation) were considered for adjuvant interferon alpha
therapy, low-doses and high doses of interferon, respect-
ively. Demographic, clinical and histological characteris-
tics of patients together with primary CM, SLNB and
CLND pathological reports, and the lymphoscintigraphy
imaging file and surgery report were collected.
Follow-up
Patients were followed up in an outpatient setting by
clinical examination one week postoperatively and then
on a six monthly basis for the first three years and every
year for the next 5 years. In addition, ultrasound analysis
of regional lymph nodes was performed in patients with
positive SLN. Tumor progression and survival status
were gathered from the hospital clinical files or by writ-
ing to family practitioners and the observations were
censored on December 31st 2010.
Statistical analysis
Statistical analysis was based on chi squared analysis or
the exact Fisher test for qualitative data and based on
Student test for quantitative data, Kaplan-Meier survival
curves and log rank analysis. The significance level was
determined at p less than 0.05. The analyses were
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Inc, Cary, NC).Results
From January 2002 to December 2009, 203 patients (100
men and 103 women) with melanoma thickness superior
to 1 mm underwent SLNB. The mean age was 56 +/− 16
(16 to 86). Clinical and histological characteristics are
shown in Table 1.Table 1 SLN: sentinel lymph node
Entire cohort Patients w
Number 203* 44/197* (2
Sex
Men 100 (49.3%) 18 (41%)
Women 103 (50.7%) 26 (59%)
Mean age (+/− SD) 55.8 +/−15.6 52.0 +/−1
Localization
Trunk 74 (36.5%) 17 (38.6%
Upper limb 39 (19.2%) 3 (6.8%)
Lower limb 63 (31.0%) 16 (36.4%
Hands and feet 27 (13.3%) 8 (18.2%)
Type
Superficial 115 (56.6%) 25 (56.8%
Nodular 39 (19.2%) 6 (13.6%)
Acral 17 (8.4%) 4 (9.1%)
Other 32 (15.8%) 9 (20.5%)
Mean tumor thickness (range) 1.88 (0.4 - 10.1) 2.8 (1.2 - 1
T stage [2]
T1 10 (4.9%) 0
T2 101 (49.7%) 15 (34.1%
T3 55 (27.1%) 17 (38.6%
T4 33 (16.3%) 11 (25.0%
Incalculable1 4 (2.0%) 1 (2.3%)
Clark level
I 1 (0.5%) 0
II 10 (4.9%) 2 (4.5%)
III 56 (27.6%) 9 (20.5%)
IV 100 (49.3%) 26 (59.1%
V 12 (5.9%) 4 (9.1%)
Unknown 24 (11.8%) 3 (6.8%)
Ulceration
Yes 60 (29.6%) 21 (47.7%
No 131 (64.5%) 20 (45.5%
Unknown 12 (5.9%) 3 (6.8%)
NS: not significant.
*6 complete or partial failures (lymphoscintigraphy and surgery).Sentinel lymph node biopsy
In all but 6 patients (3%), SLN was identified. A
complete failure (absence of reliable scintigraphic im-
aging and surgical localization) was observed in two
patients with truncal melanoma. A surgical failure (i.e.
absence of SLN sample) despite scintigraphic localiza-
tion was reported in two patients with upper limb
melanoma. SLN localization and excision could not be
carried out in two patients because there was no percu-
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lymph nodes in one patient, and CLND was then per-
formed and was negative. The axillary tissue harvested
during SLNB procedure did not contain any lymph
nodes in one patient. These 6 patients had not under-
gone blue dye marking.
The SLN identification rate was 97%. The mean num-
ber of SLN harvested was 1.5 +/− 1. Only one SLN was
harvested in 67% of cases. Nodal basin included unilat-
eral axilla (87 cases), unilateral groin (85 cases), bilateral
axillae (11 cases), bilateral groins (1 case), popliteal fossa
(2 cases) and epitrochlear (0 case). The drainage area for
limb melanomas was always homolateral (data non
shown). Drainage to multiple node fields was present in
37 cases (18%) and most of them (57%) originated from
dorsal melanomas. Of patients with trunk melanoma, 13
demonstrated interval nodes (17%). Of patients with
limbs melanoma, we observed interval nodes, including
popliteal (9 patients, 14%), and epitrochlear nodes (2
patients, 5%). Of these 24 patients with interval nodes,
11 had samples taken surgically, demonstrating a melan-
oma micrometastasis in three patients.
Of the 197 patients in whom a SLN was identified, 44
(22%) were tumor positive. We observed a statistically
significant difference between positive and negative SLN
patients for tumor thickness (p = 0.0289), the presence
of ulceration (p = 0.008), and T stage (p = 0.0172) in pri-
mary CM.
Complete lymph node dissection and adjuvant therapy
Of the patients with positive SLN, 95% (42 of 44
patients) underwent additional CLND. One patient had
a popliteal positive SLN and refused further surgical
intervention and one patient had contraindications for
radical lymphadenectomy. None of them relapsed.
Eleven patients (25%) had further pathologically positive
lymph nodes. Of the patients with positive SLN, 29%
were treated with interferon alpha. Eleven patients (7%)
with negative SLN but with a high-risk primaryTable 2 Site of initial recurrence by sentinel lymph node stat
Number all patients SLN
SLN status 197 44 (2
Recurrence:
Yes 34 (17%) 14 (3
No 163 (83%) 30 (6
Site of initial recurrence*:
Local/in transit 17 (50%) 9 (64
Regional lymph node 16 (47%) 6 (43
Distant metastatic 20 (59%) 8 (57
*Some patients may present multiple sites of recurrence.
SLN: sentinel lymph node.
NS: not significant.melanoma (tumor thickness > 4 mm and ulceration)
were treated with interferon.
Recurrence
Patients were followed for a median duration of
39.5 months (range: 5 – 97). Fifteen patients (5 SLN
positive patients and 10 SLN negative) were lost to fol-
low-up.
Thirty-four patients (17%) relapsed. Recurrences were
significantly more frequent (p = 0.002) in SLN positive
patients (32%) than in SLN negative patients (13%). The
median time for recurrence in our cohort was 12 months
(range: 0–58 months), with no significant difference be-
tween SLN positive and negative patients (15.2 +/−
15.6 months versus 17.4 +/− 16.6 months, respectively,
p = 0.7107). The site of initial recurrence is shown in
Table 2. There was no significant difference in the type
of recurrence between positive and negative SLN
patients. The result of CLND in SLN positive patients
did not lead to any significant differences in terms of re-
lapse, type of relapse or death (data not shown).
The percentage of false-negative patients in our cohort
was 6.5%, as 10 of the 153 SLN negative patients devel-
oped regional lymph node relapse. Sensitivity, specificity
and the positive and negative predictive values of the
SLN status (Table 3) in terms of recurrence were 41%,
81%, 32% and 87% respectively. Sensitivity, specificity
and the positive and negative predictive values of the
SLN status in terms of mortality were 39%, 80%, 20%
and 91% respectively.
Survival analyses
The overall cohort mortality rate was 11.3%. The mortal-
ity rate (Figure 1) was significantly higher in the SLN
positive group than in the SLN negative group (20.4%
versus 7.5%, p = 0.01). The 5-year overall survival (OS)
rate was 84.6% for all patients, but was significantly
higher for SLN negative patients as compared to SLN
positive patients (90.3% versus 69.7%; p = 0.0096). Theus
positive patients SLN negative patients p
2%) 153 (78%)
2%) 20 (13%) 0.002
8%) 133 (87%)
%) 8 (40%) NS
%) 10 (50%) NS
%) 14 (70%) NS
Table 3 SLN status sensitivity, specificity, positive
predictive value (PPV) and negative predictive value
(NPV) in terms of recurrence and mortality
SLN + SLN - Number of patients
Recurrence 14 (TP) 20 (FN) 34
No recurrence 30 (FP) 133 (TN) 163
Death 9 (TP) 14 (FN) 23
Living 35 (FP) 139 (TN) 174
Number of patients 44 153 197
TP: true-positive; TN: true-negative; FP: false positive; FN: false-negative.
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all patients, but was significantly higher in SLN negative
patients than in SLN positive patients (85.0% versus
58.7%; p = 0.0006) (Figure 2).
Adverse events
Post-operative complications of SLN biopsy (neuro-
pathic pain, infection, seroma, hematoma, lymphedema)
were observed in 12% of patients (24/197). Three
patients presented with severe complications such as
cellulitis (2 patients) and severe invalidating complexFigure 1 Kaplan-Meier curve for overall survival according to sentineregional pain syndrome occurred in one patient after a
brachial plexus injury. Post-operative complications of
additional CLND were observed in 14% of patients (6/
42), including lymphedema (3), hematoma (1) and
neuropathic pain (1) and complex regional pain syn-
drome (1).Discussion
Despite the small number of patients in our cohort, our
results confirm previous studies on SLN analysis in mel-
anoma [3,4,8-11], in terms of SLN identification rate
(97%), percentage of SLN positive patients (22%) and
percentage of additional positive CLND (25%). We also
observed a significant association between positive SLN
and primary tumor thickness and microscopic ulcer-
ation. Although only one SLN was harvested in 67% of
our cases, the mean number of SLN harvested was 1.5 +/−
1 in our study, very similar to those found by previ-
ous studies [8,12]. Furthermore, Gershenwald 7. [9]
found that among the 343 patients who underwent
CLND, the majority (72%) had only one positive SLN as
compared to 67% in our study. To our knowledge, therel lymph node (SLN) status.
Figure 2 Kaplan-Meier curve for disease-free survival according to sentinel lymph node (SLN) status.
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imal or maximal number of SLN that should be harvested
during the procedure.
As expected, recurrences were significantly more fre-
quent in SLN positive patients (32%) than in SLN nega-
tive patients (13%) suggesting a better regional control
of melanoma progression after SLNB and immediate
CLND. The rate of locoregional lymph node relapses
after lymph node excision in SLN positive patients var-
ied between 0 and 20% [4,13]. Conversely, locoregional
relapses after LND of clinically palpable lymph node pal-
pation varied between 20 and 50% [13-15]. It is nonethe-
less still difficult to know whether better regional lymph
node control is related to complementary CLND per-
formed after positive SLN is discovered. Another study
[13] retrospectively compared two groups of SLN posi-
tive patients from different hospitals, some of whom
underwent additional CLND. The authors found no sig-
nificant difference in terms of survival between the two
groups. In our study, relapse and mortality rates in SLN
positive patients were not influenced by the result of
additional CLND casting further doubt on the benefits
of complementary surgery.The SLNB was considered false-negative if a primary
recurrence developed in the regional lymph node basin
from which a tumor-free SLN had been removed. In our
study, the number of false-negative (10/153 = 6.5%) was
similar (3-8%) to other studies [11,16,17]. However, there
is ongoing debate on how to correctly calculate the
false-negative rate. It should not be expressed as a per-
centage of the total population, but rather as the number
of false-negative results divided by the number of false-
negatives and true-positives [18]. In our study, the false
negative rate (10/54 = 18.5%) was also similar to the rate
calculated in other studies (5.7% to 21%) [14]. Beyond
the technical problems associated with the SLN proced-
ure, false negatives may be related to different factors:
the time it takes to learn to perform the technique [19],
lymphatic drainage disruption related to primary tumour
excision, lymphatic obstruction by tumor cell embolism,
the presence of a neck SLN [7], inadequate histological
analysis and hematogenous dissemination.
The risk factors for recurrence after negative SLN are
identical to those observed after positive SLN: presence
or absence of macroscopic ulceration and tumoral thick-
ness superior to 4 mm [7]. Analysis of all relapses
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showed a poor sensitivity (41%) and positive predictive
value (32%) for SLN analysis but good specificity (81%)
and negative predictive value (87%). Although rarely
calculated, these values are similar to those found by
Saltman et al. [6] The same analysis focused on mortal-
ity confirmed the good specificity (80%) and negative
predictive values (91%), i.e. similar to the findings of
Morton et al. [4].
Our overall survival rates at 5 years (69.7% and 90.3%
for SLN positive and negative patients, respectively)
were similar to previous prognostic values of SLN ana-
lysis [8,20] when followed by additional CLND. A multi-
variate analysis of an international cohort of 2313 stage
III patients [20] showed that the overall survival rate at
5 years was greater in patients presenting with microme-
tastases than in patients with palpable lymph node me-
tastases (67% vs 43%). However, there were wide
variations (23% to 87%) in patients with micrometastases
depending on histological characteristics of primary mel-
anoma (ulceration, mitotic index), its anatomical
localization, number of SLN affected and patient age
[20]. A bayesian analysis was recently carried out of
studies with more than 50 patients undergoing SLN be-
tween 1993 and 2010 [11]. The authors focused on the
prognostic benefit of the SLN analysis in terms of spe-
cific survival for melanoma with tumor thickness be-
tween 1 and 4 mm. For these patients, the risk of
melanoma-related death varied between 26.2% and
31.6% when SLN was positive versus 9.7% and 15.6%
when SLN was negative.
All of these results for relapse and survival involve the
combination of two surgical procedures: research and
analysis of SLN followed by additional CLND in the
event of micrometastases in SLN. At the present time,
no advantages of lymph node excision have been shown
in terms of regional monitoring of metastatic damage or
overall survival [13,15,21]. However, an additional lymph
node excision is more often recommended when the
SLN is invaded [22].
Many attempts have been made to predict non-SLN
(NSLN) metastasis in the additional lymph node exci-
sion performed after positive SLN based on demo-
graphic, primary tumor, and SN features of patients with
melanoma. Previous studies [9,10,23-25] indicate that
overall SLN tumor burden, primary tumor thickness,
and number of SLN harvested may be useful in identify-
ing a group at low risk for positive NSLN. It is nonethe-
less interesting that these two parameters are also
predictive for SLN micrometastases [20,26]. However,
marked variability in the correlation of individual fea-
tures with NSLN metastases and the degree of this cor-
relation has characterized the literature on this issue to
date [27,28]. There is currently no consensus regardingwhat degree of risk of NSLN involvement indicates that
it is safe to forego CLND. Before elimination of CLND
can be advocated, prospective clinical trials designed to
assess the safety of omitting formal CLND with respect
to survival and locoregional control in low-risk groups
are needed. The ongoing Multicenter Selective Lympha-
denectomy Trial II [29] which compares CLND versus
close observation with sonography and clinical examin-
ation for patients with a positive SLN, should provide
valuable information about which patients might be
spared a CLND.
The frequency of post-operative complications (neuro-
pathic pain, infection and lymphocele) observed in our
study was similar to other studies in terms of morbidity
related to SLN analysis [30].Conclusions
In conclusion, our retrospective study confirms the
results of SLN analysis in patients with melanoma with
tumor thickness greater than 1 mm. The main benefit of
this analysis was the prognostic value in terms of relapse
and survival (as long as additional lymph node excision
was performed), and its high predictive negative value.
The usefulness of complementary excision is still a sub-
ject of debate due to the high percentage of normal
results and morbidity. Although already recommended,
evaluating the benefit of additional CLND after positive
SLN is necessary. New SLN analysis techniques are also
under evaluation in order to lower operative morbidity
[31].
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